FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Philippe Rousselot

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Phenomena

Recurrence

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Philippe Rousselot; Olivier Saint-Jean; Christian Berthou; Anne Bornand; Pascale Cony-Makhoul; François Guilhot; Joelle Guilhot; François Xavier Mahon; Franck Nicolini; Delphine Réa; Josy Reiffers
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.
Aline Tanguy-Schmidt; Marie-Christiane Vekemans; Jean-Paul Vernant; Jean-Yves Cahn; Jean-Michel Cayuela; Yves Chalandon; André Delannoy; Hervé Dombret; Martine Escoffre; Sandrine Hayette; Françoise Huguet; Norbert Ifrah; Delphine Réa; Philippe Rousselot; Xavier Thomas
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Laurence Legros; Stéphane Giraudier; Françoise Huguet; Franck-Emmanuel Nicolini; Philippe Rousselot; Michel Tulliez; François-Xavier Mahon
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Philippe Rousselot (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Philippe Rousselot; Olivier Saint-Jean; Christian Berthou; Anne Bornand; Pascale Cony-Makhoul; François Guilhot; Joelle Guilhot; François Xavier Mahon; Franck Nicolini; Delphine Réa; Josy Reiffers
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.
American journal of hematology 2013;88(1):1-4.
2013: Aline Tanguy-Schmidt; Marie-Christiane Vekemans; Jean-Paul Vernant; Jean-Yves Cahn; Jean-Michel Cayuela; Yves Chalandon; André Delannoy; Hervé Dombret; Martine Escoffre; Sandrine Hayette; Françoise Huguet; Norbert Ifrah; Delphine Réa; Philippe Rousselot; Xavier Thomas
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(1):150-5.
2012: Laurence Legros; Stéphane Giraudier; Françoise Huguet; Franck-Emmanuel Nicolini; Philippe Rousselot; Michel Tulliez; François-Xavier Mahon
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
Blood 2012;120(9):1959-60.
2012: Joëlle Guilhot; Michele Baccarani; Francisco Cervantes; Richard E Clark; François Guilhot; Andreas Hochhaus; Sergei Kulikov; Jiri Mayer; Andreas L Petzer; Gianantonio Rosti; Philippe Rousselot; Giuseppe Saglio; Susanne Saussele; Bengt Simonsson; Juan-Luis Steegmann; Andrey Zaritskey; Rüdiger Hehlmann
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood 2012;119(25):5963-71.
2012: Delphine Rea; Philippe Rousselot; françois guilhot; Joelle Guilhot; François-Xavier Mahon
Curing chronic myeloid leukemia.
Current hematologic malignancy reports 2012;7(2):103-8.
2012: Sylvie Castaigne; Sylvie Chevret; Nathalie Contentin; Noémie de Gunzburg; Thierry de Revel; Hervé Dombret; Pierre Fenaux; Lauris Gastaud; Estelle Henry; Ollivier Legrand; Jean-Pierre Marolleau; Cécile Pautas; Claude Preudhomme; Emmanuel Raffoux; Oumedaly Reman; Philippe Rousselot; Christine Terré; Xavier Thomas; Pascal Turlure; Ahmad Aljijakli; Jean-Noel Bastie; Dominique Bordessoule
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Lancet 2012;379(9825):1508-16.
2011: Bob Löwenberg; Giovanni Martinelli; Petra Muus; Gert Ossenkoppele; Sophie Rigaudeau; Philippe Rousselot; Pieter Sonneveld; Paul Stockman; Sergio Amadori; Ellin Berman; Jean-Yves Cahn; Stefan Faderl; Alison Goudie; Norbert Ifrah; Elias Jabbour; Mojca Jongen-Lavrencic; Hagop Kantarjian
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Blood 2011;118(23):6030-6.
2011: Catherine Roche-Lestienne; Philippe Rousselot; Valérie Coiteux; C Frimat; Martine Gardembas; françois guilhot; J Guilhot; N Helevaut; E Labis; Laurence Legros; F-X Mahon; A Marceau; O Nibourel; F Nicolini; Claude Preudhomme
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
Leukemia 2011;25(10):1661-4.
2011: Bénédicte Deau; Martine Gardembas; Agnès Guerci; François Guilhot; Joelle Guilhot; Denis Guyotat; Sandrine Hayette; Francoise Huguet; Laurence Legros; François-Xavier Mahon; Mauricette Michallet; Franck E Nicolini; Cécile Pautas; Delphine Réa; Christian Berthou; Sylvie Castaigne; Jean-Michel Cayuela; Pascale Cony-Makhoul; Isabelle Radford Weiss; Philippe Rousselot
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Leukemia research 2011;35(6):777-82.
2011: Mathilde Hunault-Berger; Thibaut Leguay; Xavier Thomas; Ollivier Legrand; Françoise Huguet; Caroline Bonmati; Martine Escoffre-Barbe; Laurence Legros; Pascal Turlure; Patrice Chevallier; Fabrice Larosa; Frederic Garban; Oumedaly Reman; Philippe Rousselot; Nathalie Dhédin; André Delannoy; Marina Lafage-Pochitaloff; Marie Christine Béné; Norbert Ifrah; Hervé Dombret
A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
Haematologica 2011;96(2):245-52.
2011: Franck E Nicolini; Sandrine Hayette; Laurence Legros; Philippe Rousselot; Frédéric Maloisel; Michel Tulliez; Agnès Guerci; Aude Charbonnier; Thomas Prébet; Françoise Rigal-Huguet; Kaddour Chabane; Jean-Pierre Magaud; Carole Paillet; Christine Pivot; Mauricette Michallet
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Leukemia research 2011;35(1):80-6.
2010: Claude Preudhomme; Joëlle Guilhot; Franck E Nicolini; Agnès Guerci-Bresler; Françoise Rigal-Huguet; Frédéric Maloisel; Valérie Coiteux; Martine Gardembas; Christian Berthou; Anne Vekhoff; Delphine Rea; Eric Jourdan; Christian Allard; Alain Delmer; Philippe Rousselot; Laurence Legros; Marc Berger; Selim Corm; Gabriel Etienne; Catherine Roche-Lestienne; Virginie Eclache; François-Xavier Mahon; François Guilhot
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
The New England journal of medicine 2010;363(26):2511-21.
2010: Cecile Pautas; Fatiha Merabet; Xavier Thomas; Emmanuel Raffoux; Claude Gardin; Selim Corm; Jean-Henri Bourhis; Oumedaly Reman; Pascal Turlure; Nathalie Contentin; Thierry de Revel; Philippe Rousselot; Claude Preudhomme; Dominique Bordessoule; Pierre Fenaux; Christine Terré; Mauricette Michallet; Hervé Dombret; Sylvie Chevret; Sylvie Castaigne
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):808-14.
2010: Neil P Shah; Dong-Wook Kim; Andrew Lamb; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Haematologica 2010;95(2):232-40.
2010: Olivia Roth; Odile Spreux-Varoquaux; Stephane Bouchet; Philippe Rousselot; Sylvie Castaigne; Sophie Rigaudeau; Victoria Raggueneau; Patrice Therond; Philippe Devillier; Mathieu Molimard; Benjamin Maneglier
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Clinica chimica acta; international journal of clinical chemistry 2010;411(3-4):140-6.
2010: Sébastien Maury; Françoise Huguet; Thibaut Leguay; Francis Lacombe; Marc Maynadié; Sandrine Girard; Adrienne de Labarthe; Emilienne Kuhlein; Emmanuel Raffoux; Xavier Thomas; Patrice Chevallier; Agnès Buzyn; André Delannoy; Yves Chalandon; Jean-Paul Vernant; Philippe Rousselot; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Marie-Christine Béné
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Haematologica 2010;95(2):324-8.
2009: A Hochhaus; M C Müller; J Radich; S Branford; H M Kantarjian; B Hanfstein; Philippe Rousselot; D-W Kim; J H Lipton; E Bleickardt; A Lambert; T P Hughes
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Leukemia 2009;23(9):1628-33.
2009: Bruno Cassinat; Stéphane de Botton; Charikleia Kelaidi; Lionel Ades; Fabien Zassadowski; Isabelle Guillemot; Marie-Helene Schlageter; Emmanuel Raffoux; Jean-Luc Harousseau; Ollivier Legrand; Martine Escoffre-Barbe; Oumedaly Reman; Martine Gardembas; Chantal Himberlin; Jean Yves Cahn; Denis Guyotat; Didier Bouscary; Anne Parry; Philippe Rousselot; Andre Baruchel; Hervé Dombret; Sylvie Chevret; Pierre Fenaux; Christine Chomienne
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).
Leukemia research 2009;33(9):1178-82.
2009: Nadia Lounnas; Catherine Frelin; Nadège Gonthier; Pascal Colosetti; Anne Sirvent; Jil-Patrice Cassuto; Fréderic Berthier; Nicolas Sirvent; Philippe Rousselot; Michel Dreano; Jean-François Peyron; Véronique Imbert
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
International journal of cancer. Journal international du cancer 2009;125(2):308-17.
2009: SAMIA MOURAH; Raphael Porcher; Géraldine Lescaille; Philippe Rousselot; Marie-Pierre Podgorniak; Géraldine Labarchède; BENYOUSSEF NAIMI; Jacques Medioni; Hervé Dombret; Fabien Calvo
Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia.
The International journal of biological markers 2009;24(1):22-31.
2008: NASR Rihab; Marie-Claude Guillemin; Omar Ferhi; Hassan Soilihi; Laurent Peres; Caroline Berthier; Philippe Rousselot; Macarena Robledo-Sarmiento; Valérie Lallemand-Breitenbach; Bernard Gourmel; Dominique VITOUX; Pier Paolo Pandolfi; Cécile Rochette-Egly; Jun Zhu; Hugues de Thé
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nature medicine 2008;14(12):1333-42.
2008: Isabelle Luquet; Jean-Luc Laï; Carole Barin; Laurence Baranger; Chrystèle Bilhou-Nabera; Eric Lippert; C Gervais; Pascaline Talmant; Pascale Cornillet-Lefebvre; Christine Perot; N Nadal; Marie-Joëlle Mozziconacci; Marina Lafage-Pochitaloff; Virginie Eclache; Francine Mugneret; C Lefebvre; Christian Herens; F Speleman; Hélène A Poirel; Isabelle Tigaud; Christine Cabrol; Philippe Rousselot; Sylvie Daliphard; Michèle Imbert; Richard Garand; Frank Geneviève; Roland Berger; Christine Terre
Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH).
Leukemia 2008;22(1):132-7.
2007: Anne Bergeron; Delphine Réa; Vincent Levy; Clément Picard; Véronique Meignin; Jérome Tamburini; Heriberto Bruzzoni-Giovanelli; Fabien Calvo; Abdellatif Tazi; Philippe Rousselot
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
American journal of respiratory and critical care medicine 2007;176(8):814-8.
2007: Andrew Lamb; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald P Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Blood 2007;109(12):5143-50.
2007: Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; françois guilhot; Giuseppe Saglio; Jane Apperley; Oliver G Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Blood 2007;109(8):3207-13.
2007: Adrienne de Labarthe; Philippe Rousselot; Françoise Huguet-Rigal; Eric Delabesse; Francis Witz; Sébastien Maury; Delphine Réa; Jean-Michel Cayuela; Marie-Christine Vekemans; Oumedaly Reman; Agnès Buzyn; Arnaud Pigneux; Martine Escoffre; Yves Chalandon; Elizabeth Macintyre; Véronique Lhéritier; Jean-Paul Vernant; Xavier Thomas; Norbert Ifrah; Hervé Dombret
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
Blood 2007;109(4):1408-13.
2007: Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean-Michel Cayuela; Odile Maarek; Odile Blanchet; Gérald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Blood 2007;109(1):58-60.
2007: Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis H Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; François-Xavier Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
Blood 2007;109(1):61-4.
2006: Brian J Druker; françois guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine 2006;355(23):2408-17.
2006: Marie Robin; Juliette Andreu-Gallien; Marie-Hélène Schlageter; Djaouida Bengoufa; Isabelle Guillemot; Katerina Pokorna; Carine Robert; Jérôme Larghero; Philippe Rousselot; Emmanuel Raffoux; Hervé Dombret; Pierre Fenaux; Marika Pla; Dominique Charron; Rose Ann Padua; Christine Chomienne
Frequent antibody production against RARalpha in both APL mice and patients.
Blood 2006;108(6):1972-4.
2006: Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-Jose Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
Blood 2006;108(6):2037-40.
2006: Christine Terré; Florence Nguyen Khac; Carole Barin; Marie-Joëlle Mozziconacci; Virginie Eclache; C Léonard; Elise Chapiro; H Farhat; A Bouyon; Philippe Rousselot; S Choquet; M Spentchian; P Dubreuil; Véronique Leblond; Sylvie Castaigne
Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases.
Leukemia 2006;20(9):1634-6.
2006: Vincent Lévy; Sarah Zohar; Christophe Bardin; Anne Vekhoff; Driss Chaoui; Bernard Rio; Ollivier Legrand; S Sentenac; Philippe Rousselot; Emmanuel Raffoux; François Chast; Sylvie Chevret; Jean-Pierre Marie
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
British journal of cancer 2006;95(3):253-9.
2006: Laure Deville; Josette Hillion; Michel Lanotte; Philippe Rousselot; Evelyne Ségal-Bendirdjian
Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias.
Current pharmaceutical biotechnology 2006;7(3):171-83.
2006: Franck E Nicolini; Selim Corm; Quoc-Hung Lê; Nathalie Sorel; Sandrine Hayette; Dominique Bories; Thibaut Leguay; L Roy; Stéphane Giraudier; Micheline Tulliez; Thierry Facon; François-Xavier Mahon; Jean-Michel Cayuela; Philippe Rousselot; Mauricette Michallet; Claude Preudhomme; françois guilhot; Catherine Roche-Lestienne
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Leukemia 2006;20(6):1061-6.
2006: Nicolas Boissel; Delphine Rea; Vannary Tieng; Nicolas Dulphy; Manuel Brun; Jean-Michel Cayuela; Philippe Rousselot; Ryad Tamouza; Philippe Le Bouteiller; François-Xavier Mahon; Alexander Steinle; Dominique Charron; Hervé Dombret; Antoine Toubert
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(8):5108-16.
2006: Frédéric Pendino; Josette Hillion; Charles Dudognon; J Delaunay; SAMIA MOURAH; Marie-Pierre Podgorniak; I Lafon; Christine Chomienne; Michel Lanotte; Hervé Dombret; Philippe Rousselot; Evelyne Ségal-Bendirdjian
Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.
Leukemia 2006;20(4):599-603.
2006: Nicolas Boissel; Philippe Rousselot; Emmanuel Raffoux; Jean-Michel Cayuela; Jean Soulier; Nuala Mooney; Dominique Charron; Hervé Dombret; Antoine Toubert; Delphine Rea
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Journal of leukocyte biology 2006;79(4):747-56.
2006: Delphine Rea; Laurence Legros; Emmanuel Raffoux; Xavier Thomas; Pascal Turlure; Sébastien Maury; Brigitte Dupriez; Arnaud Pigneux; B Choufi; Oumedaly Reman; D Stéphane; Bruno Royer; Magda Vigier; M Ojeda-Uribe; Christian Recher; Hervé Dombret; Francoise Huguet; Philippe Rousselot
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Leukemia 2006;20(3):400-3.
2006: Alban Aubry; Raphaël Porcher; Julie Bottero; Sophie Touratier; Thierry Leblanc; Benoît Brethon; Philippe Rousselot; Emmanuel Raffoux; Jean Menotti; Francis Derouin; Patricia Ribaud; Annie Sulahian
Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.
Journal of clinical microbiology 2006;44(2):389-94.
2006: Franck E Nicolini; Kaddour Chabane; Jean-Michel Cayuela; Philippe Rousselot; Xavier Thomas; Sandrine Hayette
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Haematologica 2006;91(1):137-8.
2005: Didier Bouscary; Laurence Legros; Micheline Tulliez; Stéphanie Dubois; Béatrice Mahe; Odile Beyne-Rauzy; Marie C Quarre; Dominique Vassilief; Bruno Varet; Achille Aouba; Martine Gardembas; Stéphane Giraudier; Agnès Guerci; Philippe Rousselot; Fanny Gaillard; Anne Moreau; Marie-Christine Rousselet; Norbert Ifrah; Pierre Fenaux; François Dreyfus
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
British journal of haematology 2005;131(5):609-18.
2005: Jean-Michel Cayuela; Philippe Rousselot; Franck E Nicolini; D Espinouse; C Ollagnier; M H Bui-Thi; Kaddour Chabane; Emmanuel Raffoux; Evelyne Callet-Bauchu; Isabelle Tigaud; Jean-Pierre Magaud; Sandrine Hayette
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Leukemia 2005;19(12):2334-6.
2005: Sophie Tardieu; Catherine Brun-Strang; Patrice Berthaud; Mauricette Michallet; françois guilhot; Philippe Rousselot; Roland Sambuc
Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
Pharmacoepidemiology and drug safety 2005;14(8):545-53.
2005: Jérôme Larghero; Nathalie Gervais; Bruno Cassinat; Jean-Didier Rain; Marie-Hélène Schlageter; Rose Ann Padua; Christine Chomienne; Philippe Rousselot
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.
Blood 2005;105(9):3743-5.
2004: Nicolas Boissel; Philippe Rousselot; Emmanuel Raffoux; Jean-Michel Cayuela; Odile Maarek; Dominique Charron; Laurent Degos; Hervé Dombret; Antoine Toubert; Delphine Rea
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.
Leukemia 2004;18(10):1656-61.
2004: Philippe Rousselot; Jérôme Larghero; Bertrand Arnulf; Joël Poupon; Bruno Royer; A Tibi; Isabelle Madelaine-Chambrin; P Cimerman; Sylvie Chevret; Olivier Hermine; Hervé Dombret; J Claude Brouet; J Paul Fermand
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Leukemia 2004;18(9):1518-21.
2004: Danielle Canioni; Pauline Brice; Eric Lepage; Myrna Chababi; Véronique Meignin; Bruno Salles; Luc Xerri; Pierre-Yves Péaud; Philippe Rousselot; Michel Peuchmaur; Philippe Solal-Céligny; Nicole Brousse
Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires.
British journal of haematology 2004;126(3):364-71.
2004: C Terre; V Eclache; Philippe Rousselot; M Imbert; C Charrin; C Gervais; M J Mozziconacci; O Maarek; H Mossafa; N Auger; N Dastugue; P Talmant; J Van den Akker; C Leonard; F N'Guyen Khac; F Mugneret; F Viguié; M Lafage-Pochitaloff; J N Bastie; G L Roux; F Nicolini; F Maloisel; N Vey; G Laurent; C Recher; M Vigier; Y Yacouben; S Giraudier; J P Vernant; B Salles; J Roussi; S Castaigne; V Leymarie; G Flandrin; michel lessard
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Leukemia 2004;18(8):1340-6.
2004: Philippe Rousselot; Jérôme Larghero; Sylvaine Labaume; Joël Poupon; Martine Chopin; Christine Dosquet; Jean-Pierre Marolleau; Anne Janin; Jean-Claude Brouet; Jean-Paul Fermand
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
European journal of haematology 2004;72(3):166-71.
2004: Olivier Hermine; Hervé Dombret; Joël Poupon; Bertrand Arnulf; François Lefrère; Philippe Rousselot; Gandhi Damaj; Richard Delarue; Jean-Paul Fermand; Jean-Claude Brouet; Laurent Degos; Bruno Varet; Hugues de Thé; Ali Bazarbachi
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(2):130-4.
2003: Martine Gardembas; Philippe Rousselot; Micheline Tulliez; Magda Vigier; Agnès Buzyn; Françoise Rigal-Huguet; Laurence Legros; Mauricette Michallet; Christian Berthou; Nathalie Cheron; Frédéric Maloisel; François-Xavier Mahon; Thierry Facon; Patrice Berthaud; Joëlle Guilhot; françois guilhot
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Blood 2003;102(13):4298-305.
2003: Jérôme Larghero; Thibaut Leguay; SAMIA MOURAH; Isabelle Madelaine-Chambrin; Anne-Laure Taksin; Emmanuel Raffoux; Jean-Noël Bastie; Laurent Degos; Patrice Berthaud; Jean-Pierre Marolleau; Fabien Calvo; Christine Chomienne; François-Xavier Mahon; Philippe Rousselot
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Biochemical pharmacology 2003;66(10):1907-13.
2003: Rose Ann Padua; Jérôme Larghero; Marie Robin; Carole le Pogam; Marie-Hélène Schlageter; Sacha Muszlak; Fric Jan; Robert R West; Philippe Rousselot; Thi Hai Phan; Liesbeth Mudde; Helene Teisserenc; Antoine F Carpentier; Scott C Kogan; Laurent Degos; Marika Pla; John M Bishop; Freda Stevenson; Dominique Charron; Christine Chomienne
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.
Nature medicine 2003;9(11):1413-7.
2003: Emmanuel Raffoux; Philippe Rousselot; Joël Poupon; Marie-Thérèse Daniel; Bruno Cassinat; Richard Delarue; Anne-Laure Taksin; Delphine Réa; Agnès Buzyn; Annick Tibi; Geneviève Lebbé; Patricia Cimerman; Christine Chomienne; Jean-Paul Fermand; Hugues de Thé; Laurent Degos; Olivier Hermine; Hervé Dombret
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2326-34.
2003: Fotini Nicolaou; Jens M Teodoridis; Heiyoung Park; Alexander Georgakis; Omid C Farokhzad; Erwin P Böttinger; Nicolas Da Silva; Philippe Rousselot; Christine Chomienne; Katalin Ferenczi; M Amin Arnaout; C Simon Shelley
CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD.
Blood 2003;101(10):4033-41.
2003: Elie Azoulay; Fabienne Fieux; Delphine Moreau; Guillaume Thiery; Philippe Rousselot; Antoine Parrot; Jean-Roger Le Gall; Hervé Dombret; Benoît Schlemmer
Acute monocytic leukemia presenting as acute respiratory failure.
American journal of respiratory and critical care medicine 2003;167(10):1329-33.
2003: françois guilhot; Martine Gardembas; Philippe Rousselot; Micheline Tulliez; Magda Vigier; Agnès Buzyn; Françoise Rigal-Huguet; Laurence Legros; Mauricette Michallet; Christian Berthou; Albert Najman; Frédéric Maloisel; François-Xavier Mahon; Thierry Facon; Patrice Berthaud; Joëlle Guilhot
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Seminars in hematology 2003;40(2 Suppl 2):92-7.
2003: Stephen G O'Brien; françois guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan Lanng Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Andrew Lamb; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
2003: Philippe Rousselot; Jérôme Larghero; Emmanuel Raffoux; Fabien Calvo; Micheline Tulliez; Stéphane Giraudier; Michel Rybojad
Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
British journal of haematology 2003;120(6):1091-2.
2003: Nicolas Boissel; Marie-Françoise Auclerc; Véronique Lhéritier; Yves Perel; Xavier Thomas; Thierry Leblanc; Philippe Rousselot; Jean-Michel Cayuela; Jean Gabert; Nathalie Fegueux; Christophe Piguet; Françoise Huguet-Rigal; Christian Berthou; Jean-Michel Boiron; Cécile Pautas; Gérard Michel; Denis Fière; Guy Leverger; Hervé Dombret; André Baruchel
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(5):774-80.
2003: Patricia Franchi-Rezgui; Philippe Rousselot; Marc Espié; Josette Brière; Jean Pierre Marolleau; Christian Gisselbrecht; Pauline Brice
Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(2):116-20.
2002: A Bergeron; E Bergot; G Vilela; Lionel Ades; A Devergie; Hélène Espérou; Gérard Socié; F Calvo; Eliane Gluckman; Patricia Ribaud; Philippe Rousselot; Abdellatif Tazi
Hypersensitivity pneumonitis related to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4271-2.
2002: Nicolas Boissel; Jean-Michel Cayuela; Claude Preudhomme; Xavier Thomas; Nathalie Grardel; Xavier Fund; Isabelle Tigaud; Emmanuel Raffoux; Philippe Rousselot; François Sigaux; Laurent Degos; Sylvie Castaigne; Pierre Fenaux; Hervé Dombret
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
Leukemia 2002;16(9):1699-704.
2002: Carlos M Galmarini; Xavier Thomas; Fabien Calvo; Philippe Rousselot; Assia El Jafaari; Emeline Cros; Charles Dumontet
Potential mechanisms of resistance to cytarabine in AML patients.
Leukemia research 2002;26(7):621-9.
2002: Carlos M Galmarini; Xavier Thomas; Fabien Calvo; Philippe Rousselot; Muriel Rabilloud; Assia El Jaffari; Emeline Cros; Charles Dumontet
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
British journal of haematology 2002;117(4):860-8.
2002: Frédéric Maloisel; Agnès Guerci; Denis Guyotat; Norbert Ifrah; Mauricette Michallet; J Reiffers; G Tertain; Michel Blanc; Frédéric Bauduer; J Brière; Jean-François Abgrall; B Pegourie-Bandelier; Eric Solary; Nathalie Cambier; Diane Coso; Jean-Pierre Vilque; Martine Delain; Jean-Luc Harousseau; Philippe Rousselot; Karim Belhadj; P Morice; J Attal; M Chabin; C Chastang; Joëlle Guilhot; françois guilhot
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Leukemia 2002;16(4):573-80.
2002: Ali Guermazi; C Feger; Philippe Rousselot; M Merad; N Benchaib; Pierre Bourrier; X Mariette; Jacques Frija; Eric de Kerviler
Granulocytic sarcoma (chloroma): imaging findings in adults and children.
AJR. American journal of roentgenology 2002;178(2):319-25.
2001: Carlos M Galmarini; Kathryn Graham; Xavier Thomas; Fabien Calvo; Philippe Rousselot; Assia El Jafaari; Emeline Cros; John R Mackey; Charles Dumontet
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
Blood 2001;98(6):1922-6.
2001: C Alberti; Adel Bouakline; Patricia Ribaud; claire lacroix; Philippe Rousselot; Thierry Leblanc; Francis Derouin
Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients.
The Journal of hospital infection 2001;48(3):198-206.
2001: R Costello; Danielle Sainty; R Bouabdallah; J P Fermand; Alain Delmer; Marine Diviné; Jean-Pierre Marolleau; Jean-Albert Gastaut; Daniel Olive; Philippe Rousselot; P Chaïbi
Primary plasma cell leukaemia: a report of 18 cases.
Leukemia research 2001;25(2):103-7.
2000: A Guermazi; S N Quoc; G Socie; Josette Briere; E de Kerviler; P Solal-Celigny; Jacques Frija; Philippe Rousselot
Myeloblastoma (chloroma) in leukemia: case 1. Granulocytic sarcoma (chloroma) of the breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3993-6.
2000: C Adida; Christian Recher; Emmanuel Raffoux; Marie-Thérèse Daniel; Anne-Laure Taksin; Philippe Rousselot; François Sigaux; Laurent Degos; Dario C Altieri; Hervé Dombret
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia.
British journal of haematology 2000;111(1):196-203.
2000: S Park; Pauline Brice; M E Noguerra; D Simon; Philippe Rousselot; Y Kerneis; Pierre Morel; Jean-Pierre Marolleau; Christian Gisselbrecht
Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
Bone marrow transplantation 2000;26(3):321-6.
2000: Irina Ionescu; Pauline Brice; D Simon; Ali Guermazi; T Leblanc; Philippe Rousselot; Dominique Gossot; Véronique Meignin; C Gisselbrecht; Jean-Didier Rain
Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.
Medical oncology (Northwood, London, England) 2000;17(2):127-34.
2000: Franck Morschhauser; Jean-Michel Cayuela; S Martini; André Baruchel; Philippe Rousselot; Gérard Socié; P Berthou; Jean-Pierre Jouet; N Straetmans; François Sigaux; Pierre Fenaux; Claude Preudhomme
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):788-94.
2000: Nicolas Da Silva; Sandrine Meyer-Monard; Marie-Laurence Menot; Antonio Parrado; A Lebel; Nicole Balitrand; Pierre Fenaux; Jean-Michel Micléa; Philippe Rousselot; Laurent Degos; Hervé Dombret; Christine Chomienne
Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(5):316-28.
1999: Jérôme Larghero; Fabien Zassadowski; Philippe Rousselot; Rose Ann Padua; Laurent Degos; Christine Chomienne
Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens.
Leukemia 1999;13(8):1295-6.
1999: Xavier Thomas; Pierre Fenaux; Hervé Dombret; S Delair; François Dreyfus; Hervé Tilly; Anne Vekhoff; Pascale Cony-Makhoul; Véronique Leblond; Xavier Troussard; Catherine Cordonnier; Thierry de Revel; M Simon; Franck E Nicolini; Anne-Marie Stoppa; Maud Janvier; Dominique Bordessoule; Philippe Rousselot; Martine Ffrench; Jean-Pierre Marie; Eric Archimbaud
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Leukemia 1999;13(8):1214-20.
1999: Jean-Philippe Rerolle; Eric Thervet; Hélène Beaufils; F Vincent; Philippe Rousselot; Evangéline Pillebout; Christophe Legendre
Crescentic glomerulonephritis and centrocytic lymphoma.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(7):1744-5.
1999: Sébastien Maury; Thierry Leblanc; Philippe Rousselot; Patrick Legrand; G Arlet; Catherine Cordonnier
Bacteremia due to Capnocytophaga species in patients with neutropenia: high frequency of beta-lactamase-producing strains.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(5):1172-4.
1999: Philippe Rousselot; Sylvaine Labaume; Jean-Pierre Marolleau; Jérôme Larghero; Maria Helena Noguera; Jean-Claude Brouet; Jean-Paul Fermand
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.
Cancer research 1999;59(5):1041-8.
1997: M André; Pauline Brice; D Cazals; C Hennequin; Christophe Fermé; Y Kerneis; Philippe Rousselot; Jean-Marc Zini; Eric Lepage; Christian Gisselbrecht
Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA).
Hematology and cell therapy 1997;39(2):59-65.
1997: Claude Gardin; P Chaibi; Thierry de Revel; Philippe Rousselot; Pascal Turlure; Jean-Michel Micléa; G Nédellec; Hervé Dombret
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Leukemia 1997;11(1):16-21.
1995: Richard Garand; Eliane Duchayne; D Blanchard; Nelly Robillard; Emilienne Kuhlein; Odile Fenneteau; F Salomon-Nguyen; M J Grange; Philippe Rousselot; Cécile Demur
Minimally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Français d'Hématologie Cellulaire.
British journal of haematology 1995;90(4):868-75.
1995: Sélim Aractingi; C Bachmeyer; J M Miclea; Olivier Vérola; Philippe Rousselot; Louis Dubertret; Marie-Thérèse Daniel
Unusual specific cutaneous lesions in myelodysplastic syndromes.
Journal of the American Academy of Dermatology 1995;33(2 Pt 1):187-91.
1995: Christine Chomienne; Fabien Guidez; J M Micléa; J N Bastie; L Delva; Philippe Rousselot; P Ballerini
[Nuclear receptors and ontogenesis of the hematopoietic tissue].
Comptes rendus des séances de la Société de biologie et de ses filiales 1995;189(4):493-501.
1994: Z Chen; Fabien Guidez; Philippe Rousselot; A Agadir; Sai-Juan Chen; wang zhenyi; Laurent Degos; Arthur Zelent; Samuel Waxman; Christine Chomienne
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(3):1178-82.
1994: Philippe Rousselot; bhushan hardas; A Patel; Fabien Guidez; Joop Gäken; Sylvie Castaigne; A Dejean; Hugues de Thé; Laurent Degos; Farzin Farzaneh
The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.
Oncogene 1994;9(2):545-51.